Dexmedetomidine Accord
HumanMedicines
Overview
By its judgment of 13 November 2024 in Case T‑223/20, the General Court annulled the Commission Implementing Decision of 13 February 2020 granting a marketing authorisation for the medicinal product Dexmedetomidine Accord (dexmedetomidine). As a result, Dexmedetomidine Accord is not considered authorised for use in the EU.
Dexmedetomidine Accord was granted marketing authorisation in the EU as a generic medicine of Dexdor on 13 February 2020 for light to moderate sedation.